"The European Commission has authorised Cablivi (caplacizumab) as the first therapeutic specifically indicated for the treatment of adults experiencing an episode of aTTP.
The condition is a life-threatening, autoimmune-based blood clotting disorder characterised by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (very low platelet count), microangiopathic hemolytic anemia (loss of red blood cells through destruction), ischemia and widespread organ damage."
- By Selina McKee for Pharma Times Online.
